Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately bullish: Nine brokerages collectively rate Lyell Immunopharma “Moderate Buy,” with six buys, one strong buy, one hold and one sell. Their average 12-month price target is $42, well above the stock’s $14.17 opening price.
• Lyell shares were trading down 4.8%, with a market capitalization of approximately $347 million and a 52-week range of $9.28 to $45.00. The company remains unprofitable, reporting a quarterly loss of $1.92 per share despite narrowly beating estimates.
• Institutional investors own 66.05% of the company’s stock. Recent activity included a new $31 million position from MWG Caph and a 194.8% stake increase by Renaissance Technologies.

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $42.00.

LYEL has been the subject of a number of research analyst reports. Zacks Research upgraded Lyell Immunopharma from a "strong sell" rating to a "hold" rating in a research report on Monday, May 18th. Stifel Nicolaus started coverage on Lyell Immunopharma in a research report on Thursday, August 6th. They set a "buy" rating and a $36.00 price target on the stock. Wall Street Zen raised Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Sunday, May 10th. Robert W. Baird set a $49.00 price objective on Lyell Immunopharma and gave the company an "outperform" rating in a report on Thursday, April 30th. Finally, B. Riley Financial initiated coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They set a "buy" rating and a $44.00 target price for the company.

Lyell Immunopharma Trading Down 4.8%

Lyell Immunopharma stock opened at $14.17 on Thursday. Lyell Immunopharma has a 52 week low of $9.28 and a 52 week high of $45.00. The stock has a market cap of $347.17 million, a price-to-earnings ratio of -1.10 and a beta of -0.04. The company's 50-day moving average price is $13.42 and its two-hundred day moving average price is $18.76.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, topping analysts' consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 87.60%. The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. Research analysts expect that Lyell Immunopharma will post -7.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Several large investors have recently made changes to their positions in the business. MWG Caph Ltd acquired a new position in shares of Lyell Immunopharma in the 4th quarter worth approximately $31,030,000. Renaissance Technologies LLC lifted its stake in Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company's stock valued at $2,335,000 after purchasing an additional 76,921 shares during the last quarter. Walleye Capital LLC acquired a new stake in Lyell Immunopharma during the first quarter valued at approximately $445,000. Dimensional Fund Advisors LP bought a new stake in Lyell Immunopharma during the first quarter worth approximately $959,000. Finally, BBR Partners LLC bought a new stake in Lyell Immunopharma during the fourth quarter worth approximately $210,000. Institutional investors own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source